Methicillin-resistant Staphylococcus aureus (MRSA) is a type of bacteria that has developed resistance to many antibiotics, making it a significant public health concern. MRSA infections can occur ...

MRSA: Methicillin-resistant Staphylococcus aureus, a type of bacteria that is resistant to many antibiotics, making infections difficult to treat. Minimum Inhibitory Concentration (MIC): The ...

Dalbavancin is under clinical development by AbbVie and currently in Phase III for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections. According to GlobalData, Phase III drugs for ...

In this study, we modeled the empiric treatment of cellulitis in the outpatient setting, incorporating estimates of the growing risk of MRSA. The increasing proportion of community-acquired ...

This indicator covers the incidence of healthcare associated infections from Methicillin-resistant Staphylococcus aureus (MRSA). It measures outcomes that reflect the quality of care or processes ...

Nearly 75% of swab samples taken from fitness equipment tested positive for Staphylococcus aureus, a type of bacteria that ...

Staphylococcus aureus, adapts to living on the human body could help improve the prevention, diagnosis, and treatment of certain infections. The study, from the Wellcome Sanger Institute ...

Staphylococcus aureus, adapts to living on the human body could help improve the prevention, diagnosis, and treatment of certain infections. The study, from the Wellcome Sanger Institute ...

Staphylococcus aureus, adapts to living on the human body could help improve the prevention, diagnosis, and treatment of certain infections. The study, from the Wellcome Sanger Institute ...

Staphylococcus aureus is a leading cause of nosocomial and community acquired infections. Methicillin-resistant S. aureus clonal types have now spread worldwide. Resistance development of MRSA has ...

Staphylococcus aureus, adapts to living on the human body could help improve the prevention, diagnosis, and treatment of certain infections. The study, from the Wellcome Sanger Institute ...

The PhD defense of A. Vlasblom will take place at the Faculty of Veterinary Medicine on Wednesday, February 5, 2025.